Targeted Therapies, a Breakthrough Treatment for Prostate Cancer
Targeted Therapies: A Pioneering Treatment for Prostate Cancer
For the last several months, the American Hospital of Paris has offered patients a highly accurate diagnosis procedure known as targeted transperineal biopsy. This innovative, painless technique, performed under local anesthesia, lowers the risk of health care-associated infection to almost zero while its high level of precision helps avoid overtreatment.
Today, the Prostate Center is innovating once again by offering targeted therapies – a revolutionary, minimally invasive treatment that uses microwave or laser energy to destroy cancerous cells. The urologist, guided by fused MRI and ultrasound images, inserts a needle through the pelvic floor directly into the tumor’s core to eliminate the tumor. Emitting microwave or laser energy, the needle destroys the tumor from the inside out, thus sparing the surrounding healthy cells.
Preserving Patients’ Quality of Life
Targeted prostate cancer therapies are minimally invasive procedures performed on an outpatient basis. They offer the benefit of being simpler, faster and better tolerated, with little pain. The benefits for patients are considerable. While traditional treatments come with two major risks—urinary incontinence and sexual dysfunction—these new targeted therapies have virtually no negative impact on quality of life.
Clinical Trial Underway
Because it deploys this innovative method, the American Hospital of Paris is one of ten urology centers in Europe that has been selected to participate in the Violette trial, which aims to precisely evaluate the effectiveness of microwave energy in the needle-based focal treatment of prostate cancer. The Hospital’s participation in this trial reflects its reputation in urology and its recognized excellence in prostate cancer treatment.
Support Medical Innovation at the American Hospital of Paris
The American Hospital of Paris is firmly committed to using methods that are not only the most innovative and effective, but also the most conducive to patients’ well-being and quality of life, regardless of the medical field. You can contribute to the development of new diagnostic and therapeutic techniques at the American Hospital of Paris by making a donation to the AHP Medical Innovation Fund. Your gift will enable us to acquire state-of-the-art equipment that is essential for developing ever more innovative medical practices, to benefit our patients.
Thank you in advance for your generosity.
Your generosity is encouraged
The American Hospital of Paris is a non-profit institution of recognized public benefit. When you make a gift to the Hospital, you may benefit from the following tax advantages:
- 75% of your donation amount can be deducted from your French IFI wealth tax on
real estate assets;
- 66% of your donation amount can be deducted from your French income tax;
- 60% of your donation amount can be deducted from your French corporate tax.
As the American Hospital of Paris is a recognized 501(c)3, your donation is also tax deductible in the United States.
As soon as we receive your donation, we will send you a tax receipt enabling you to claim your tax reduction.
Your support is acknowledged
- For any donation of €5,000 or more, your name will be included in our 2021 annual report.
“Targeted therapies require a personalized approach with practices that are ‘customized’ based on the tumor’s location and aggressiveness.
To offer these various techniques, a wide range of energy sources must be available. At the American Hospital today, we mainly use microwave- and laser-based therapies.
Thank you for enabling us to deploy this groundbreaking method, for the benefit of our patients. ”
Dr Aurel Messas, Urologist and pioneer in targeted therapies
